Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Autifony Initiates Phase I Study for AUT00063 for Hearing Loss and Tinnitus Treatment

Published: Monday, June 10, 2013
Last Updated: Monday, June 10, 2013
Bookmark and Share
Company tops up Series A financing with further £5.5 million investment.

Autifony Therapeutics Limited has announced the start of a Phase I clinical study of the novel, first-in-class Kv3 potassium channel modulator, AUT00063.

This is a randomized, placebo controlled Phase I study, conducted in the UK, to investigate the safety, tolerability and pharmacokinetics of orally administered single and multiple dose regimens of AUT00063 in around 60 young and elderly volunteers.

The study, which is also exploring a variety of novel pharmacodynamic endpoints and interactions, is expected to be completed in Q1 2014.

AUT00063 is being developed as a treatment for age-related hearing loss and tinnitus. Despite the fact that 50% of those aged over 60 suffer from age-related hearing loss and 10% of the population suffer from some form of tinnitus, there are currently no effective treatments for either condition.

AUT00063 is a novel pharmaceutical that targets auditory processing in the brain. Deficits in these central mechanisms are believed to contribute to hearing difficulties in the elderly as well as the emergence of tinnitus.

To fund this lead programme through to clinical Proof-of-Concept for at least one hearing disorder indication, Autifony has also announced that Pfizer Venture Investments, the venture capital arm of Pfizer Inc., has invested £5 million to join existing investors SV Life Sciences, Imperial Innovations plc and UCL Business plc (UCL-B) in the Series A financing round.

Dr Elaine Jones from Pfizer has joined the Autifony board. The International Biotechnology Trust PLC (IBT) has also invested, bringing the total funds raised to date to £15.75 million.

Dr Charles Large, Chief Scientific Officer of Autifony Therapeutics, commented: “We are delighted by the progress that has been made to bring AUT00063 into clinical development. Hearing loss and tinnitus affect the lives of a vast proportion of the population, yet there are no effective treatments available. AUT00063 has the potential to change that.

“We welcome the financial commitment from Pfizer and IBT, in addition to SV Life Sciences, Imperial Innovations, and UCL-B, which will allow us to explore the therapeutic potential of this first-in-class medicine. Our current intent is to partner the programme, for which we hold unencumbered global rights, once we have achieved clinical proof of concept and we are encouraged by the interest shown to date by pharmaceutical companies.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dr John Hutchison Joins Autifony Therapeutics as Chief Medical Officer
Dr Hutchison brings a wealth of experience of clinical drug development in both big pharma and the biotech sector.
Friday, September 04, 2015
Autifony Awarded £2.2 Million to Progress AUT00063 for Tinnitus into Phase IIa Study
Award follows successful completion of Phase I.
Wednesday, June 04, 2014
Autifony Announces Collaboration with Universities of Manchester and Newcastle
£2.75 million research collaboration to progress a first-in-class drug for schizophrenia.
Monday, July 01, 2013
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Apricot Kernels Pose Risk of Cyanide Poisoning
Eating more than three small raw apricot kernels, or less than half of one large kernel, in a serving can exceed safe levels. Toddlers consuming even one small apricot kernel risk being over the safe level.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
A lncRNA Regulates Repair of DNA Breaks in Breast Cancer Cells
Findings give "new insight" into biology of tough-to-treat breast cancer.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!